Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.
The company's shares are trading at their lowest since August 2023. Source: xStation
US OPEN: āļāļ§āļēāļĄāļāļķāļāļāļąāļāļāļĨāļąāļāļĄāļēāđāļāļāđāļ§āļāļāđāļāļŠāļąāļāļāļēāļŦāđ
Nvidia: āđāļāļāļąāļŠāđāļāļāļĩāđāļāļēāļĢāļāļąāļāļŠāđāļ H200 āđāļāļāļĩāļāļāļĩāđāļāļēāļāđāļāļīāļāļāļķāđāļ
āļāđāļēāļ§āđāļāđāļāļ§āļąāļāļāļĩāđ
āļŦāļļāđāļ Lam Research āļāļĢāļąāļāļāļąāļ§āļāļķāđāļ āļŦāļĨāļąāļāļāļąāļāļ§āļīāđāļāļĢāļēāļ°āļŦāđāļāļĢāļąāļāļāļģāđāļāļ°āļāļģāđāļŦāļĄāđ
